Valuing Post-Revenue Biopharmaceutical Assets with Pfizer's Current Portfolio as a Case Study

no code implementations • 4 Dec 2023 • Yongzhuo Chen, Yixuan Liang, Yiran Liu, Brian Hobbs, Michael Kane

This research paper addresses the critical challenge of accurately valuing post-revenue drug assets in the biotechnology and pharmaceutical sectors, a key factor influencing a wide range of strategic operations and investment decisions.

Decision Making